The DTWD1 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the MES-OV human ovarian cancer cell line, designed to disrupt the DTWD1 gene. This product provides a heterogeneous loss-of-function model to investigate the role of DTWD1, a putative tRNA methyltransferase, in epithelial ovarian cancer. The cells are supplied as an uncloned pool, ensuring broad representation of genetic backgrounds while targeting the gene of interest.
MES-OV is a widely used cell line derived from a human ovarian adenocarcinoma, serving as a representative model of epithelial ovarian cancer. It retains key oncogenic features such as aberrant proliferation, migration capacity, and tumorigenicity in vivo, making it suitable for mechanistic studies and preclinical drug evaluation.
DTWD1 is predicted to function as a tRNA methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to specific tRNA residues. This post-transcriptional modification is critical for tRNA structural integrity and decoding fidelity, directly impacting the efficiency and accuracy of ribosomal protein synthesis. The enzymatic activity of DTWD1 positions it as a key node linking tRNA processing to translation regulation. In the absence of DTWD1, tRNAs may lack essential methylation marks, potentially leading to reduced translation of certain mRNAs or global proteome shifts. Although the upstream signals controlling DTWD1 expression and its direct interaction partners are currently unknown, its downstream effects are mediated through tRNA substrates and the broader protein synthesis machinery. This model therefore enables dissection of how a single tRNA modification enzyme influences the cellular proteome.
In the MES-OV ovarian cancer background, DTWD1 knockout provides a means to interrogate the importance of tRNA methylation in sustaining malignant phenotypes. Altered translation is a hallmark of cancer, and dysregulated tRNA modifications have been observed in various tumors. By disrupting DTWD1, researchers can study whether loss of tRNA methyltransferase activity impairs ovarian cancer cell proliferation, survival, or invasiveness. This system is particularly useful for identifying synthetic lethal interactions or for testing the hypothesis that cancer cells are more dependent on accurate translation than normal cells. Moreover, it may reveal vulnerabilities that can be exploited pharmacologically, supporting drug target validation efforts.
The polyclonal nature of these knockout cells preserves genetic heterogeneity, making them suitable for a range of downstream applications. Researchers can employ tRNA methylation-specific assays to directly measure modification levels, while western blotting and RT-qPCR allow assessment of candidate protein and transcript changes. Proliferation, colony formation, migration, and invasion assays enable functional characterization. Transcriptome profiling via RNA-seq can uncover global impacts on gene expression. These cells also facilitate drug sensitivity testing and genome-wide screens. For further information or to discuss specialized protocols, please contact Ascent Research.
